Physician profile
Daniel R Martinez
NPI 1801022421
$133,308.85
in general payments reported to CMS, 2019-2025
55 companies · $15K in 2025
The $15K reported for 2025 was more than what 95% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $11K · 2021: $9,089 · 2022: $6,782 · 2023: $49K · 2024: $27K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $47K · Consulting Fee: $20K · Travel and Lodging: $16K · Food and Beverage: $8,720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,955.00 |
| Consulting Fee | $19,500.00 |
| Travel and Lodging | $16,158.51 |
| Food and Beverage | $8,720.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $73,056.33 | 2019-2024 | Xiaflex |
| Endo USA, INC. | $30,345.80 | 2024-2025 | Xiaflex |
| Metuchen Pharmaceuticals | $15,941.62 | 2019-2020 | |
| Coloplast Corp | $6,973.50 | 2019-2025 | Titan, Speedicath |
| 180 Medical, INC. | $1,506.73 | 2019-2025 | Gentlecath, Gentlecath Glide |
| Boston Scientific Corporation | $486.79 | 2020-2025 | Ams 700 |
| Clarus Therapeutics INC. | $405.36 | 2021 | |
| Convatec INC. | $350.59 | 2021-2023 | |
| Medtronic, INC. | $349.59 | 2022-2023 | Micra |
| Teleflex LLC | $342.01 | 2023-2025 | Urolift, Barrigel |
| Astellas Pharma US INC | $269.35 | 2019-2023 | Myrbetriq |
| Verity Pharmaceuticals INC. | $250.95 | 2024-2025 | Tlando |
| Sumitomo Pharma America, INC. | $244.71 | 2023-2025 | Gemtesa |
| Janssen Biotech, INC. | $239.53 | 2020-2025 | Erleada |
| Antares Pharma, INC. | $218.76 | 2019-2025 | Xyosted, Tlando, Nocdurna |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.